InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promising results for NV-387, its lead drug candidate, in treating Measles. In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%—from 7.4 to 17 days—with no observed toxicity and dose-dependent efficacy. The drug mimics human cell features to bind and neutralize viruses, targeting over 90% of…